Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Advances and considerations in the treatment and management of HR+, HER2-, advanced breast cancer

Hans-Christian Kolberg • 13 May 2020
ESMO Breast 2020
Breast Cancer

Hans-Christian Kolberg, MD, PhD, of the Marienhospital Bottrop, Bottrop, Germany, discusses recent advances and considerations in the treatment and management of HR+, HER2-, advanced breast cancer including the use of CDK4/6 inhibitors and the importance of targeting PI3K as well as PIK3CA mutation testing. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Hans-Christian Kolberg

3:57
NeoMono: mono atezolizumab window followed by atezolizumab - CTX vs atezolizumab - CTX
Hans-Christian Kolberg • 7 Dec 2022
4:53
Comparing therapy benefit from initially HER2 positive or negative metastatic breast cancer patients
Hans-Christian Kolberg • 26 May 2021
2:41
Key updates from the St Gallen Consensus Session
Hans-Christian Kolberg • 22 Mar 2021
3:14
ABP 980, a trastuzumab biosimilar in combination with pertuzumab
Hans-Christian Kolberg • 22 Mar 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals